Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyLinkers Having a Crucial Role in Antibody-Drug ConjugatesStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsAntibody Drug Conjugates: Preclinical ConsiderationsMylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationSIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomasTargeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationAddition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Obligate multivalent recognition of cell surface tomoregulin following selection from a multivalent phage antibody library.High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyRandomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMARas-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinGemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.Prodrugs for improving tumor targetability and efficiency.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinEmerging treatments in acute myeloid leukaemia.Human leukaemic stem cells: a novel target of therapy.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyIdarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.Recent advances in targeted therapy of human myelogenous leukaemia.The role of gemtuzumab ozogamicin in acute leukaemia therapy.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Molecular target therapy for synovial sarcoma.Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsMonoclonal antibody-based therapeutics for leukemia.Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupThe role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinUse of antibodies and immunoconjugates for the therapy of more accessible cancers.EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinomaSiglecs as targets for therapy in immune-cell-mediated disease.
P2860
Q24678297-843484C3-D488-400D-8208-796B44FD7118Q26752763-C6B4296F-F3B0-49FD-9DA5-0F34D58A850CQ26780335-0C580C4F-6FB2-4A27-B1C9-1E2798D9F0D7Q27022321-22135963-BD89-4E3D-9640-8F8AA2120279Q28207989-6E6EE8F3-2A88-4887-B121-1F4F262AB58DQ28237131-43F6AFB7-5A45-4894-918F-E682144ECFF4Q28476825-0ABDF110-8665-4A5A-AA0C-1A3D60C4798FQ30835785-7593D6AC-1DFF-45CB-ADAC-02B4CE1F7117Q33263079-199BDE4D-6218-414D-9E2B-E0735408BA22Q33373033-4A3FA959-89BF-4CAD-924E-F93DC58DFCA5Q33412354-6701D2DC-31F0-4EDD-A643-418F0940E77DQ33418153-DCD623AE-9B64-46B5-BC9E-3A63473B5721Q33558088-D2C08FF2-AD0A-4C51-BFFA-0311D4C2EC08Q33828797-B0B44A16-1987-4939-BCC2-C6DCF5E198B4Q34973413-108B9D76-D3B0-448E-B76E-D68E19E74009Q35029920-7C78F87A-E3F9-48C1-983A-F4D1CD151235Q35034815-C0595EF5-72EE-443E-AFA6-7E948A9F3FF1Q35095165-17B55E5E-E57E-45E2-AFFD-2E0F5E1FD960Q35459059-02E37D73-C7EB-4140-A221-F6BFBA1530BEQ35717808-E440621E-C4DA-4987-B7FB-AFD86B9BA44AQ35779278-78087B12-47CD-4215-92A0-8403F171331BQ35854964-1CE588FC-B4A0-4BEB-824F-714478E940A1Q35854970-629480B4-4EDA-4BAF-B429-763A969644D3Q35980938-9850BBC8-8650-4606-AF91-61E324CAC3EBQ36058588-CA53DD1F-FB0D-4AF0-AC1E-2BD8C2CB72FEQ36158816-95D98587-4C0D-4799-8906-8DA67E04199FQ36214426-D0E57392-D276-472E-BF1A-E745537FDC14Q36216376-C6D8F191-CE0B-4E85-A7CC-5D5EACB81BE2Q36318531-568F29EC-A813-49C5-84CF-8C2DB4888688Q36367816-492D7EF3-337B-476C-9723-A8BDEA4156E4Q36407249-AA487B65-E100-4C54-ABAB-F96651335DCEQ36429636-99849124-AE2E-4EAC-B577-205F7DFD2A29Q36591404-6ED844A8-1C4A-41DC-9A4D-A26E5AD12158Q36739759-56D82D95-1003-42D6-9469-05753B59A69BQ36805474-F7D9261C-EDD3-4C3C-A860-4A6BE32E619AQ36832124-F26D33B0-FA4D-41D4-8050-8485C18C6E4FQ36932014-F88CA89E-9893-423D-B2F0-55D5CB83025FQ37174938-B01E1994-7758-4B8E-9F31-E253422CD221Q37329160-BC0653E8-D46E-4361-B6B7-B9300D158F31Q37440061-E3D8C11D-D52A-4F7E-BB89-1E6637C18AC1
P2860
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@ast
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@en
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg
@nl
type
label
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@ast
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@en
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg
@nl
prefLabel
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@ast
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@en
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg
@nl
P2093
P1433
P1476
Targeting of the CD33-calichea ...... emic and normal myeloid cells.
@en
P2093
Bernstein ID
Hoogeveen PG
Houtsmuller AB
te Marvelde JG
van Der Velden VH
van Dongen JJ
P304
P356
10.1182/BLOOD.V97.10.3197
P407
P577
2001-05-01T00:00:00Z